Nifedipine Compared to Atosiban for Treating Preterm Labor

Raed Salim145 enrolled

Overview

The purpose of this study is to investigate the efficacy and the safety of nifedipine compared to atosiban for treating preterm labor.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

145

Conditions

Labor, Premature

Interventions

AtosibanDRUG

Atosiban group will receive an atosiban bolus (6.75 mg) over 1 min then an intravenous infusion of 300mcg/min for 3 h followed by 100mcg/min for another 45h. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, atosiban will be stopped and the women will receive nifedipine as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.

NifedipineDRUG

Nifedipine group: the initial dose will be 20 mg (one tab) orally every 20 min for 3 doses. If the contractions is inhibited, a maintenance dose of 20 - 40 mg every 6 h up to 48 h will be followed. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, nifedipine will be stopped and the women will receive atosiban as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Inclusion Criteria: 1. Gestational age between 24 to 34 weeks which had been documented by a definite LMP and sonography up to 20 weeks. 2. All women fulfilled the criteria of preterm labor. The diagnosis of preterm labor required the presence of 4 uterine contractions or more over 30 minutes, each lasting at least 30 seconds, and documented cervical change. The cervical criteria were met when either of the following was present: 1. Nulliparous women: a single cervical examination demonstrating dilatation of 0 cm to 4 cm and effacement of at least 50% 2. Multiparous women: a single cervical examination demonstrating dilatation of 1 cm to 4 cm and effacement of at least 50%. 3. Provision of written informed consent Exclusion Criteria: 1. Chorioamnionitis 2. Preterm rupture of membranes 3. Vaginal bleeding 4. Major fetal malformations 5. Severe hypertensive disorders 6. Intrauterine growth restriction (\< 5th percentile). 7. Non-reassuring fetal heart rate 8. Maternal contraindications 1. Chronic hypertension 2. Systolic blood pressure \< 90 mmHg 3. Cardiovascular disease 4. Elevated hepatic enzymes 9. Congenital or acquired uterine malformation

Locations (1)

HaEmek Medical Center

Afula, Israel

Outcomes

Primary Outcomes

delaying labor

Time frame: for more than 48 hours after starting treatment

Secondary Outcomes

drugs side effects

Time frame: within the first 48 hours after treatment

obstetrical (number of days to delivery, gestational age at delivery, mode of delivery)

Time frame: within 24 hours after delivery

neonatal (Apgar score, sepsis, IVH, NEC, RDS, DEATH)

Time frame: within 30 days from delivery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.